4.3 Article

Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch

Journal

CTS-CLINICAL AND TRANSLATIONAL SCIENCE
Volume 10, Issue 2, Pages 84-92

Publisher

WILEY
DOI: 10.1111/cts.12455

Keywords

-

Ask authors/readers for more resources

US Food and Drug Administration (FDA)-approved diagnostic assays play an increasingly common role in managing patients to prolong lifespan while also enhancing quality of life. Diagnostic assays can be essential for the safe and effective use of therapeutics (companion diagnostic), or may inform on improving the benefit/risk ratio without restricting drug access (complementary diagnostic). This tutorial reviews strategic considerations for drug and assay development resulting in FDA-approved companion or complementary diagnostic status.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available